Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New registry focuses on rheumatic immune-related AEs of cancer therapy

Key clinical point: Most rheumatic immune-related adverse events resulting from cancer therapy were not severe, could be verified by C-reactive protein and imaging, and were readily treatable.

Major finding: The large majority of patients had an elevated C-reactive protein level (76%) and pathology on joint ultrasound (96%); most cases (80%) were manageable with prednisone either alone or combined with NSAIDs.

Study details: A multicenter registry cohort study of 69 patients having rheumatic symptoms as a result of immune checkpoint inhibitor therapy or other cancer therapies.

Disclosures: The study did not receive any specific funding. Dr. Benesova disclosed grant/research support from AbbVie, Novartis, Rheumaliga Baden-Wurttemberg, and the University of Heidelberg, and consultancies, speaker fees, and/or travel reimbursements from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Medac, Merck Sharp & Dohme, Mundipharma, Novartis, Pfizer, Roche, and UCB. Some of her coauthors also disclosed financial relationships with industry.